

**NOVOGEN LIMITED**  
(ASX: NRT)



**ASX RELEASE**  
19 December 2013

## **Novogen to Present at Biotech Showcase 2014 in San Francisco 14 January 2014**

**19 December 2013, Sydney, Australia:** Novogen Limited, an oncology drug development company, announced today that CEO and Executive Chairman, Dr Graham Kelly, will be presenting at the Biotech Showcase 2014 on Tuesday January 14 at 2.00 pm. The conference is being held at the Wyndham Parc 55 Hotel.

Dr Graham Kelly said today, “This is the start of a concerted campaign in 2014 to introduce the Company and its technologies to US and European investors. 2013 has been a year of consolidating our intellectual property, of identifying the opportunity, and of determining both our R&D strategy and commercial objectives. In light of the importance of what we are endeavoring to bring to the field of cancer therapy, we believe it now is appropriate to bring these matters into a greater public forum.”

### **About Novogen**

Novogen Ltd is a public, Australian biotechnology company whose shares trade on both the Australian Securities Exchange (‘NRT’) and NASDAQ (‘NVGN’). The Company is based in Sydney, Australia, and with a US office in New Haven, Connecticut. The Company has two main drug technology platforms known as super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs target cancer stem cells and are being developed for the treatment of ovarian cancer and glioblastoma. ATM drugs target the cancer cell cytoskeleton and are being developed for the treatment of melanoma, prostate cancer and neuroblastoma. Novogen has entered into a joint venture with Yale University known as CanTx Inc with the aim of developing personalized chemotherapy for patients with ovarian cancer.

### **Further information**

Contact Dr Graham Kelly, Chief Executive Officer.  
Tel: 61 2 9476 0344  
Fax: 61 2 9476 0388  
Mobile: (61) 0429 854 390

16-20 Edgeworth David Ave, Hornsby, NSW, 2077, AUSTRALIA  
PO Box 2333 Hornsby Westfield, NSW, 1635, AUSTRALIA

Email: [Graham.Kelly@novogen.com](mailto:Graham.Kelly@novogen.com)

Further information is available on the Company’s website, [www.novogen.com](http://www.novogen.com)